Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company ...

"Successful second quarter for Camurus" Summary second quarter 2025 April - June Total revenues grew 52% (65% at CER1) to SEK 676 (445) million Sales of Buvidal® increased 17% (26% at CER1) to SEK ...

Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company’s ...

Camurus AB (STO:CAMX) presented its second quarter 2025 results on July 17, revealing record financial performance and significant progress across its product portfolio.

Camurus AB (CAMRF) reports a 52% revenue increase, strategic licensing with Eli Lilly, and EU approval of Oczyesa, despite currency challenges and market hurdles.

Camurus AB (STO:CAMX) presented its second quarter 2025 results on July 17, revealing record financial performance and significant progress across its product portfolio. The Swedish specialty ...

Baxdrostat is a highly selective, second-generation, nonimidazole aldosterone synthase inhibitor; 100 times less baxdrostat ...

View the latest Camurus AB (CAMRF) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

Investing.com -- Almirall (BME: ALM) shares rose on Friday after the company reported a 72.1% increase in net income for the ...

An investigational antihypertensive drug resolved or reduced hypertension in patients with primary aldosteronism, according to a small phase IIa trial. By week 12, systolic blood pressure was ...